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Arsenic may be most well-known as a poison and carcinogen, but its potential for medical use is also not 
entirely new. Arsenic trioxide’s (ATO) history has its start in traditional Chinese medicine under the 
name Pi-Shuang, serving as a versatile therapy through its external application1. ATO has since made 
its way into western medicine as an FDA-approved therapeutic for acute promyelocytic leukemia2. A 
cousin to ATO, inorganic sodium arsenite 
(iAs) also shows promise as a cell cycle 
inhibitor in a variety of cell lines, including the 
human adenocarcinoma breast cancer cell 
line MCF-73. However, the carcinogenic 
effects of chronic exposure to low-dose iAs 
remains troublesome. Understanding the 
dual roles of iAs and ATO as both promoters 
and inhibitors of cancer is critical for their 
successful application as therapeutics. 
 
In this issue of Cell Cycle, Lynn A. Sheldon 
advances the field by unraveling the role of 
iAs in blocking cell proliferation4. She details 
the effects of iAs on key regulators of the 
G1/S transition—E2F family transcription 
factors, the retinoblastoma protein (Rb), 
cyclins, and cyclin-dependent kinases (Cdk). 
E2F1 activates genes required for entry into 
S-phase, including factors for DNA synthesis 
and positive regulators of the cell cycle 
(Figure 1)5. During quiescence, E2F1 is 
inhibited by a hypo-phosphorylated form of 
Rb6. As the cell transitions to S-phase, Cdks 
are activated by their respective cyclins and 
phosphorylate Rb. This hyper-
phosphorylated form of Rb releases E2F1, 
allowing transcription of its target genes.  
 
Sheldon measured the effects of iAs on 
MCF-7 cells released from quiescence4.  She 
first found that while the transcription of 
cyclin E2 was decreased, cyclins E1 and D1 
levels remained unaffected (Figure 1). The study thus narrows on the pathway directly pertaining to 
cyclin E2, including its binding partner Cdk2 and the Cdc25a phosphatase, which activates Cdk2 by 
removing an inhibitory phosphate. Sheldon found that upon exposure of cells to iAs, both Cdk2 activity 
and Cdc25a transcription decreased. She next probed downstream components of the pathway and 
Figure 1. Summary of iAs effects on regulators of G1/S 
phase. Protein interactions (shown as solid arrows or lines) 
and transcriptional targets (dotted arrows) along the E2F1-
Rb pathway. All components of this pathway showed 
decreased activity or transcription after treatment with iAs, 
with the exception of Rb, whose activity is increased. 
	
found that levels of activating E2F transcription factors (E2F1, E2F2, E2F3a) were also decreased. In a 
ChIP assay, Sheldon observed an increased presence of Rb and E2F1 at the E2F1 promoter and 
subsequently found that two Rb sites (T373 and S608) were less phosphorylated, which would promote 
dimerization with E2F1. She concludes that in cells treated with iAs, increased inhibition of E2F1 by 
hypo-phosphorylated Rb is the likely mechanism by which the cell cycle is blocked in G1. 
 
Sheldon’s careful study shows the profound effect of iAs on the E2F1-Rb cell cycle pathway, and 
incites more exciting questions regarding the role of iAs. Which member of this pathway is the direct 
target of iAs, and which protein interactions or enzyme activities are affected? Sheldon postures the 
interesting hypothesis that it is not a lack of kinase activity that leads to Rb dephosphorylation and E2F1 
inhibition, but rather an active dephosphorylation of Rb by the protein phosphatases PP1 or PP2A. PP2A 
dephosphoylates Rb in response to oxidative stress, a known outcome of iAs introduction7. With respect 
to translating iAs to the clinic, the next important question is whether iAs interactions can be fine-tuned to 
specifically harness its anti-proliferative effects. The community eagerly awaits further details that 
distinguish mechanisms underlying the harmful and beneficial effects of this potential anti-cancer agent. 
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